{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:08:01Z","timestamp":1779192481463,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Intramural Research Program of the National Institutes of Health"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.antiviral.2017.03.025","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T01:44:16Z","timestamp":1491356656000},"page":"30-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-6359","authenticated-orcid":false,"given":"Neeltje","family":"van Doremalen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darryl","family":"Falzarano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianlei","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-7758","authenticated-orcid":false,"given":"Emmie","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trenton","family":"Bushmaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana P.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2300-1818","authenticated-orcid":false,"given":"Patrick W.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimiter S.","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent J.","family":"Munster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.03.025_bib1","doi-asserted-by":"crossref","first-page":"31629","DOI":"10.1038\/srep31629","article-title":"Passive Transfer of A Germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal Middle East respiratory syndrome coronavirus infection","volume":"6","author":"Agrawal","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2017.03.025_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/s40064-015-1490-9","article-title":"Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol","volume":"4","author":"Arabi","year":"2015","journal-title":"Springerplus"},{"issue":"9","key":"10.1016\/j.antiviral.2017.03.025_bib3","doi-asserted-by":"crossref","DOI":"10.3201\/eid2209.151164","article-title":"Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia","volume":"22","author":"Arabi","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.03.025_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijid.2016.06.015","article-title":"Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis","volume":"49","author":"Badawi","year":"2016","journal-title":"Int. J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.antiviral.2017.03.025_bib5","first-page":"389","article-title":"Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis)","volume":"60","author":"Brining","year":"2010","journal-title":"Comp. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2017.03.025_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"39","key":"10.1016\/j.antiviral.2017.03.025_bib7","doi-asserted-by":"crossref","DOI":"10.2807\/ese.17.39.20285-en","article-title":"Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction","volume":"17","author":"Corman","year":"2012","journal-title":"Euro Surveill."},{"issue":"33","key":"10.1016\/j.antiviral.2017.03.025_bib8","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1073\/pnas.1510199112","article-title":"Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus","volume":"112","author":"Corti","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"41","key":"10.1016\/j.antiviral.2017.03.025_bib9","doi-asserted-by":"crossref","first-page":"16598","DOI":"10.1073\/pnas.1310744110","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques","volume":"110","author":"de Wit","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.antiviral.2017.03.025_bib10","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJMoa1405858","article-title":"Transmission of MERS-coronavirus in household contacts","volume":"371","author":"Drosten","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"8","key":"10.1016\/j.antiviral.2017.03.025_bib11","doi-asserted-by":"crossref","first-page":"e1004250","DOI":"10.1371\/journal.ppat.1004250","article-title":"Infection with MERS-CoV causes lethal pneumonia in the common marmoset","volume":"10","author":"Falzarano","year":"2014","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.antiviral.2017.03.025_bib12","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1128\/JVI.00661-15","article-title":"Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits","volume":"89","author":"Haagmans","year":"2015","journal-title":"J.\u00a0Virol."},{"issue":"10","key":"10.1016\/j.antiviral.2017.03.025_bib13","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/infdis\/jiw080","article-title":"Prophylaxis with a MERS-CoV-specific human monoclonal antibody protects rabbits from MERS-CoV infection","volume":"213","author":"Houser","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"issue":"4","key":"10.1016\/j.antiviral.2017.03.025_bib14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"234","key":"10.1016\/j.antiviral.2017.03.025_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1126\/scitranslmed.3008140","article-title":"Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein","volume":"6","author":"Jiang","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2017.03.025_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/cr.2015.113","article-title":"A\u00a0humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein","author":"Li","year":"2015","journal-title":"Cell Res."},{"issue":"326","key":"10.1016\/j.antiviral.2017.03.025_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1061","article-title":"Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in\u00a0vivo","volume":"8","author":"Luke","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.antiviral.2017.03.025_bib18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann. Intern Med."},{"issue":"1","key":"10.1016\/j.antiviral.2017.03.025_bib19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"issue":"7","key":"10.1016\/j.antiviral.2017.03.025_bib20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nm.4131","article-title":"A\u00a0roadmap for MERS-CoV research and product development: report from a World Health Organization consultation","volume":"22","author":"Modjarrad","year":"2016","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.antiviral.2017.03.025_bib21","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJMc1215691","article-title":"Pneumonia from human coronavirus in a macaque model","volume":"368","author":"Munster","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"12","key":"10.1016\/j.antiviral.2017.03.025_bib22","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3201\/eid2112.151421","article-title":"Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea","volume":"21","author":"Park","year":"2015","journal-title":"Emerg. Infect. Dis."},{"issue":"28","key":"10.1016\/j.antiviral.2017.03.025_bib23","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1073\/pnas.1510830112","article-title":"Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection","volume":"112","author":"Pascal","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.antiviral.2017.03.025_bib24","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/infdis\/jiu539","article-title":"Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza","volume":"211","author":"Ramos","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"issue":"9","key":"10.1016\/j.antiviral.2017.03.025_bib25","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1073\/pnas.1222878110","article-title":"Genomic responses in mouse models poorly mimic human inflammatory diseases","volume":"110","author":"Seok","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"19","key":"10.1016\/j.antiviral.2017.03.025_bib26","doi-asserted-by":"crossref","first-page":"E2018","DOI":"10.1073\/pnas.1402074111","article-title":"Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution","volume":"111","author":"Tang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2017.03.025_bib27","series-title":"Position Paper on Collection and Use of Convalescent Plasma or Serum as an Element in Middle East Respiratory Syndrome Coronavirus Response","author":"WHO","year":"2014"},{"key":"10.1016\/j.antiviral.2017.03.025_bib28","series-title":"Coronavirus Infections","author":"WHO","year":"2015"},{"key":"10.1016\/j.antiviral.2017.03.025_bib29","series-title":"WHO-ISARIC Joint MERS-CoV Outbreak Readiness Workshop: Clinical Management and Potential Use of Convalescent Plasma 10\u201312 December 2013","author":"WHO and ISARIC","year":"2013"},{"issue":"6","key":"10.1016\/j.antiviral.2017.03.025_bib30","first-page":"530","article-title":"Pharmacokinetic characteristics of therapeutic antibodies","volume":"13","author":"Wohlrab","year":"2015","journal-title":"J.\u00a0Dtsch. Dermatol Ges."},{"issue":"5","key":"10.1016\/j.antiviral.2017.03.025_bib31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J.\u00a0Antimicrob. Chemother."},{"issue":"14","key":"10.1016\/j.antiviral.2017.03.025_bib32","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1128\/JVI.00912-14","article-title":"Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies","volume":"88","author":"Ying","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.03.025_bib33","doi-asserted-by":"crossref","first-page":"8223","DOI":"10.1038\/ncomms9223","article-title":"Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody","volume":"6","author":"Ying","year":"2015","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.antiviral.2017.03.025_bib34","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1128\/JVI.00446-15","article-title":"Passive immunotherapy with dromedary immune serum in an experimental animal model for middle East respiratory syndrome coronavirus infection","volume":"89","author":"Zhao","year":"2015","journal-title":"J.\u00a0Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216305381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216305381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T12:24:25Z","timestamp":1568982265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216305381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":34,"alternative-id":["S0166354216305381"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.03.025","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}